Methylselenocysteine – a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs

Hypoxia-Specific Drug Tirapazamine Does Not Abrogate Hypoxic Tumor Cells in Combination Therapy with Irinotecan and Methylselenocysteine in Well-Differentiated Human Head and Neck Squamous Cell Carcinoma A253 Xenografts

(2015) Arup Bhattacharya et al.   NEOPLASIA

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

(2011) J. F. de Groot et al.   NEURO-ONCOLOGY

Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer

(2010) N M Corcoran et al.   BRITISH JOURNAL OF CANCER

Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1α

(2010) Sreenivasulu Chintala et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Antiangiogenesis agents in colorectal cancer

(2010) Joleen Hubbard et al.   CURRENT OPINION IN ONCOLOGY

Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer

(2010) Giorgio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of metastatic renal cell carcinoma

(2010) Maxine Sun et al.   Nature Reviews Urology

Architectural Heterogeneity in Tumors Caused by Differentiation Alters Intratumoral Drug Distribution and Affects Therapeutic Synergy of Antiangiogenic Organoselenium Compound

(2010) Youcef M. Rustum et al.   Journal of Oncology

Renal Effects of Anti-angiogenesis Therapy: Update for the Internist

(2009) Faina Gurevich et al.   AMERICAN JOURNAL OF MEDICINE

Metabolism of selenium compounds catalyzed by the mammalian selenoprotein thioredoxin reductase

(2009) Jun Lu et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Inhibition of Colon Cancer Growth by Methylselenocysteine-Induced Angiogenic Chemomodulation Is Influenced by Histologic Characteristics of the Tumor

(2009) Arup Bhattacharya et al.   Clinical Colorectal Cancer

Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents

(2009) Maurizio Zangari et al.   JOURNAL OF CLINICAL ONCOLOGY

The Negative Results of the SELECT Study Do Not Necessarily Discredit the Selenium-Cancer Prevention Hypothesis

(2009) Karam El-Bayoumy   NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL

Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite

(2008) Guang-xun Li et al.   CARCINOGENESIS

Tumor Vascular Maturation and Improved Drug Delivery Induced by Methylselenocysteine Leads to Therapeutic Synergy with Anticancer Drugs

(2008) A. Bhattacharya et al.   CLINICAL CANCER RESEARCH

Selenium and anticarcinogenesis: underlying mechanisms

(2008) Matthew I Jackson et al.   CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE

Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers

(2008) Scott M. Lippman et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Combination of antiangiogenesis with chemotherapy for more effective cancer treatment

(2008) J. Ma et al.   MOLECULAR CANCER THERAPEUTICS

Why does cytotoxic chemotherapy cure only some cancers?

(2008) Philip Savage et al.   Nature clinical practice. Oncology

Selenium as an anticancer nutrient: roles in cell proliferation and tumor cell invasion

(2007) Huawei Zeng et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY